Highly purified, plasma-derived factor IX (FIX) concentrates are produced i
n large part by a combination of anion exchange and heparin affinity chroma
tography. However, the concentrates still contain some accompanying protein
s. The main impurity has turned out to be the adhesive glycoprotein, vitron
ectin. It occurs in concentrates exclusively in its multimeric form, in con
trast to the situation in plasma. The multimeric vitronectin can be removed
either by nanofiltration with a crossflow system or by size-exclusion chro
matography. When these FIX concentrates are used as therapeutic agents, the
fact has to be taken into account that considerable amounts of multimeric
vitronectin are given to the patient. The physiological consequences of the
dosage of this protein have not yet been investigated. Although no thrombo
genicity has been reported in connection with the above-mentioned FIX conce
ntrates, we recommend that the impurity should be removed from the preparat
ion with the methods described here.